BARC

Eliana Merle

Q: How accurate are Eliana Merle's stock ratings?

About 58% of Eliana's ratings were profitable over a one-year hold, with an average return of +12.7% per rating, measured by 13Foresight from historical prices.

Q: How is Eliana ranked?

Eliana Merle is ranked #879 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Barclays

Wall Street Analyst

★★★★☆

#879

on 13Foresight · ranked by our own returns

59%

Success Rate

+13.1%

Average Return

54 of 91 calls profitable · +8.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 59% of Eliana Merle's ratings turned a profit when each position was held for 1 year — averaging +13.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

142 Buy 32 Hold 4 Sell

Eliana's Stock Coverage 38 ratings · 2026-08-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BMRN BioMarin Pharmaceutical	Aug 10, 2026	BUY	Strong Buy +36.7% avg upside 52 analysts	$105.00 50.75% Upside	+1.9%	·
MBX MBX Biosciences, Inc.	Aug 07, 2026	BUY	Strong Buy +17.9% avg upside 14 analysts	$88.00 33.83% Upside	-2.6%	·
SABS SAB Biotherapeutics	Aug 07, 2026	BUY	Strong Buy +184.4% avg upside 14 analysts	$13.00 246.65% Upside	·	·
RGNX RegenXBio	Aug 07, 2026	HOLD	Strong Buy +257.8% avg upside 22 analysts	$12.00 12.99% Upside	+0.0%	·
ASND Ascendis Pharma	Aug 07, 2026	BUY	Strong Buy +8.4% avg upside 24 analysts	$345.00 35.83% Upside	-0.3%	·
SRPT Sarepta Therapeutics	Aug 07, 2026	HOLD	Buy +233.1% avg upside 49 analysts	$20.00 12.06% Upside	+0.0%	·
INSM Insmed	Aug 07, 2026	BUY	Strong Buy +33.2% avg upside 37 analysts	$237.00 79.61% Upside	+1.4%	·
KYMR Kymera Therapeutics	Aug 06, 2026	BUY	Strong Buy -3.4% avg upside 37 analysts	$139.00 28.37% Upside	+2.0%	·
VRTX Vertex Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy -15.5% avg upside 62 analysts	$617.00 16.23% Upside	+9.0%	·
MRNA Moderna	Aug 05, 2026	HOLD	Hold +17.8% avg upside 38 analysts	$48.00 20.81% Downside	+13.2%	·
RARE Ultragenyx Pharmaceutical	Aug 05, 2026	BUY	Strong Buy +147.0% avg upside 36 analysts	$43.00 58.97% Upside	+7.7%	·
REGN Regeneron	Aug 05, 2026	BUY	Strong Buy -2.1% avg upside 58 analysts	$917.00 13.87% Upside	+2.1%	·
MDGL Madrigal Pharmaceuticals	Aug 03, 2026	BUY	Strong Buy -4.8% avg upside 33 analysts	$962.00 81.29% Upside	+11.1%	·
PTCT PTC Therapeutics	Aug 03, 2026	BUY	Strong Buy +9.8% avg upside 29 analysts	$120.00 63.86% Upside	+7.0%	·
ALNY Alnylam Pharma	Aug 03, 2026	BUY	Strong Buy +46.8% avg upside 51 analysts	$450.00 104.87% Upside	+1.4%	·
QURE uniQure	Jul 30, 2026	BUY	Strong Buy +31.2% avg upside 29 analysts	$60.00 33.37% Upside	+7.0%	·
IONS Ionis Pharmaceuticals	Jul 30, 2026	BUY	Strong Buy +42.3% avg upside 43 analysts	$90.00 62.17% Upside	+6.9%	·
ALT Altimmune	Jul 28, 2026	BUY	Strong Buy +793.0% avg upside 20 analysts	$20.00 567.83% Upside	+3.0%	·
GOSS Gossamer Bio	Jul 28, 2026	SELL	Buy +3647.8% avg upside 17 analysts	$0.28 52.94% Upside	+11.3%	·
BBIO BridgeBio Pharma	Jul 09, 2026	BUY	Strong Buy +11.5% avg upside 34 analysts	$157.00 86.49% Upside	-6.1%	·
IVA Inventiva	Jun 04, 2026	BUY	Strong Buy +235.3% avg upside 17 analysts	$18.00 280.10% Upside	+12.3%	·
TYRA Tyra Bioscience	Jun 03, 2026	BUY	Strong Buy +75.8% avg upside 17 analysts	$59.00 135.87% Upside	-8.5%	·
SGMT Sagimet Biosciences, Inc. Class A	Apr 02, 2026	HOLD	Strong Buy +195.1% avg upside 15 analysts	$8.00 16.29% Downside	+79.0%	·
FDMT 4D Molecular Therapeutics	Jan 27, 2026	BUY	Strong Buy +210.4% avg upside 15 analysts	$33.00 188.71% Upside	+26.6%	·
BNTX BioNTech SE	Nov 06, 2025	HOLD	Strong Buy +44.3% avg upside 26 analysts	$117.00 25.63% Upside	-10.2%	·
ANAB AnaptysBio	Aug 12, 2025	HOLD	Strong Buy +26.8% avg upside 26 analysts	$20.00 64.71% Downside	+327.9%	·
GILD Gilead Sciences	Aug 08, 2025	HOLD	Strong Buy -12.1% avg upside 66 analysts	$112.00 17.74% Downside	+14.5%	·
ARWR Arrowhead Pharmaceuticals	Jul 21, 2025	HOLD	Strong Buy -15.9% avg upside 27 analysts	$12.00 86.42% Downside	+406.6%	·
PROK ProKidney	Jul 15, 2025	BUY	Buy +309.0% avg upside 12 analysts	$8.00 398.44% Upside	-52.5%	·
ARVN Arvinas Holding Company	May 15, 2025	BUY	Buy +219.9% avg upside 28 analysts	$21.00 135.48% Upside	+45.1%	·
ZNTL Zentalis Pharmaceuticals	Jan 28, 2025	HOLD	Buy +239.3% avg upside 18 analysts	$2.20 46.98% Downside	+6.7%	·
RVMD Revolution Medicines	Jan 08, 2025	BUY	Strong Buy -17.9% avg upside 32 analysts	$71.00 65.34% Downside	+141.8%	·
KOD Kodiak Sciences	Apr 04, 2024	HOLD	Buy +19.4% avg upside 11 analysts	$5.00 88.07% Downside	-42.4%	·
GLUE Monte Rosa Therapeutics	Oct 13, 2022	BUY	Strong Buy +41.0% avg upside 15 analysts	$22.00 40.54% Upside	-38.6%	·
RNAC Cartesian Therapeutics	Mar 03, 2021	BUY	Strong Buy +268.0% avg upside 19 analysts	$10.00 16.45% Upside	-57.2%	·
LKFT Lakefront Biotherapeutics	Aug 19, 2020	HOLD	Buy +271.6% avg upside 24 analysts	$134.00 367.24% Upside	-59.9%	·
PRQR ProQR	Dec 11, 2019	BUY	Strong Buy +498.2% avg upside 18 analysts	$40.00 1972.61% Upside	-51.1%	·
WHWK Whitehawk Therapeutics	Mar 18, 2019	BUY	Buy +167.8% avg upside 14 analysts	$8.00 68.80% Upside	-63.1%	·

🔒 33 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Eliana Merle — Frequently Asked Questions

How accurate are Eliana Merle's stock ratings?

Based on the calls 13Foresight could measure, about 58% of Eliana's ratings were profitable over a one-year hold, with an average return of +12.7% per rating, or +8.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Eliana ranked on 13Foresight?

Eliana Merle is currently ranked #879 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Eliana cover?

Eliana most recently has ratings on BMRN, MBX, SABS, RGNX, ASND, SRPT, INSM, KYMR, VRTX, MRNA, RARE, REGN and 26 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Eliana Merle

Rating Distribution

Welcome to 13Foresight!